☆ 4.5 Article

Longitudinal determination of BNT162b2 vaccine induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers

VACCINE (2022)

Related references

Note: Only part of the references are listed.

Article Infectious Diseases

Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel

Vivian Glueck et al.

Summary: The study found that individuals with a history of COVID-19 who received a booster vaccination showed high levels of antibodies, much higher than those after recovery. Healthy individuals who received two doses of vaccine also achieved similar levels of antibodies, and memory T cell counts were not correlated with antibody levels. None of the study participants experienced reinfection.

INFECTION (2022)

Add to Collection

Article Medicine, General & Internal

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Arabella S. Stuart et al.

Summary: The study investigated the mixed use of different COVID-19 vaccines within the same schedule, showing that in certain conditions, heterologous vaccination can achieve similar immunogenicity to homologous vaccination, facilitating rapid global vaccine deployment.

LANCET (2022)

Add to Collection

Article Multidisciplinary Sciences

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

Sandile Cele et al.

Summary: The study found that the Omicron variant has reduced neutralizing effectiveness in individuals vaccinated with Pfizer BNT162b2, but those who had previously been infected with SARS-CoV-2 showed better neutralization against Omicron.

NATURE (2022)

Add to Collection

Letter Medicine, General & Internal

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

Shirley Collie et al.

Summary: Preliminary data from a test-negative study design in South Africa showed that two doses of the BNT162b2 vaccine had an efficacy of 50 to 70% against hospitalization caused by the omicron variant in Gauteng province.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review

Edward P K Parker et al.

Lancet Global Health (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

Lauren B. Rodda et al.

Summary: The study found that individuals recovered from mild COVID-19 develop sustained SARS-CoV-2-specific immunological memory for at least 3 months, including immunoglobulin antibodies, neutralizing plasma, and memory B and T cells. These memory lymphocytes exhibit potent antiviral function, aiding in immune defense.

CELL (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Charlotte Manisty et al.

LANCET (2021)

Add to Collection

Letter Medicine, General & Internal

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

Maria Prendecki et al.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Annette B. Vogel et al.

Summary: The two vaccine candidates, BNT162b1 and BNT162b2, developed contain modified messenger RNA encoding immunogens derived from the spike glycoprotein of SARS-CoV-2. They have shown promising immune responses in mice and rhesus macaques, with ongoing phase I trials in Germany and the USA and a global phase II/III trial for BNT162b2.

NATURE (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Florian Krammer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Immunology

SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond

Emily Bettini et al.

Summary: To successfully protect against pathogen infection, a vaccine must trigger efficient adaptive immunity involving B and T cell responses. mRNA vaccines have become leaders in the race to develop an effective COVID-19 vaccine due to their rapid development capabilities and ability to induce robust adaptive immune responses.

VACCINES (2021)

Add to Collection

Article Multidisciplinary Sciences

Diverse functional autoantibodies in patients with COVID-19

Eric Y. Wang et al.

Summary: COVID-19 patients show increased autoantibody reactivities against immunomodulatory proteins, which may affect immune function and lead to different clinical outcomes.

NATURE (2021)

Add to Collection

Article Infectious Diseases

2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness

Robyn Ralph et al.

JOURNAL OF INFECTION IN DEVELOPING COUNTRIES (2020)

Add to Collection

Editorial Material Multidisciplinary Sciences

A strategic approach to COVID-19 vaccine R&D

Lawrence Corey et al.

SCIENCE (2020)

Add to Collection

Editorial Material Immunology

The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement

Peter J. Hotez et al.

MICROBES AND INFECTION (2020)

Add to Collection

Article Medicine, Research & Experimental

SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia

Wei Chen et al.

BIOMEDICINE & PHARMACOTHERAPY (2020)

Add to Collection

Article Multidisciplinary Sciences

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Mark J. Mulligan et al.

NATURE (2020)

Add to Collection

Editorial Material Infectious Diseases

The complexities of SARS-CoV-2 serology Comment

Catherine F. Houlihan et al.

LANCET INFECTIOUS DISEASES (2020)

Add to Collection

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

Add to Collection

Article Cell Biology

Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients

Carl A. Pierce et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Microbiology

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Jeffrey Seow et al.

NATURE MICROBIOLOGY (2020)

Add to Collection

Article Microbiology

Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection

Annabelle Stroemer et al.

MICROORGANISMS (2020)

Add to Collection

Article Multidisciplinary Sciences

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Ania Wajnberg et al.

SCIENCE (2020)

Add to Collection

Article Immunology

Priming with SARS CoVS DNA and boosting with SARS CoVS epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses

Jun Huang et al.

VACCINE (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.